The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-Segment Elevation Myocardial Infarction: vascular healing outcomes from the MAGSTEMI trial

DOI: 10.4244/EIJ-D-20-00198

1. Hospital Univeritari de Bellvitge, Institut d' Investigació Biomedica de Bellvitge (IDIBELL), L' Hospitalet de Llobregat, Spain, Spain
2. Hospital Clínic i Provincial de Barcelona, IDIBAPS (Institut d’Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Spain
3. Hospital Clínic i Provincial de Barcelona, IDIBAPS (Institut d’Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Spain.
4. Hospital Universtiario La Princesa, Instituto de Investigación Sanitaria-IP, Madrid, Spain
5. Hospital San Pedro de Alcántara, Cáceres, Spain
6. Hospital Universitari de Sant Pau, Barcelona, Spain
7. Hospital Clínico San Carlos; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain
8. Hospital Universitari Vall d’Hebrón; Barcelona, Spain
9. Hospital Puerta de Hierro-Majadahonda, Madrid, Spain
10. Hospital Ramón y Cajal, Madrid, Spain
11. Hospital Universitari de Bellvitge, Institut d’ Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L’ Hospitalet de Llobregat, Spain
12. Hospital Universitari de Bellvitge, Institut d’ Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L’ Hospitalet de Llobregat, Spain.
13. Hospital Universtiario La Princesa, Instituto de Investigación Sanitaria-IP, Madrid, Spain.
14. Hospital Universitari de Sant Pau, Barcelona, Spain.
15. Hospital Universitari Vall d’Hebrón; Barcelona, Spain.
16. Hospital General de Alicante; Spain.
17. Hospital Alvaro Cunqueiro, Vigo, Spain
Disclaimer:

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.

Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.

To read the full content of this article, please log in to download the PDF.

The MAGSTEMI trial showed larger angiographic lumen loss and restenosis with Magnesium-based bioresorbable scaffold (MgBRS) than with sirolimus-eluting stent (SES). Ninety-five patients (MgBRS=48 and SES=47) underwent to OCT imaging at 1 year. Devices with indiscernible struts were observed in 33.3% vs. 0% (p<0.001); struts integrated into the vessel wall in 22.9% vs. 63.8% (p<0.001); protruding struts in 37.5% vs. 31.9% (p=0.568), and; protruding and malapposed struts in 6.3% vs. 4.3% (p=0.663), respectively. Minimal lumen area (3.92±2.02 vs. 6.31±1.71mm; p<0.001) and expansion index (0.58±0.16 vs. 0.86±0.19; p<0.001) were smaller with MgBRS. The main cause of MgBRS restenosis was scaffold collapse (50%). Further generations of MgBRS should prolong the radial force.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Major infections after PCI or surgery, drug-coated balloons in NSTEMI, left atrial appendage closure versus direct oral anticoagulants, TAVI in nonagenarians, and "CAVI"